Diarrhoea News and Research

RSS

New research shows childhood diarrhea cases significantly higher than estimated

The number of cases of childhood diarrhoea attributable to pathogens (bacteria, parasites, viruses or other infections) have been substantially underestimated and may be nearly twice as high as previous analysis suggests, according to new research published in The Lancet.

24 Sep 2016

Research strongly links smoking to bowel condition relapses

Smoking is strongly linked to relapse of a serious bowel condition, research has confirmed.

31 Aug 2016

Cases of rotavirus infections fall by 84% thanks to vaccination

Figures published by Public Health England have shown that the number of diagnosed Rotavirus cases, a highly infectious virus which may cause vomiting and diarrhoea, have dropped by 84% since the introduction of a vaccine to the national childhood immunisation schedule in July 2013.

29 Aug 2016

Crohn's disease sufferers experience slower cognitive response times, study shows

New research published in the UEG Journal1 has found that Crohn's disease sufferers experience slower response times than matched individuals that do not have the disease.

25 Aug 2016

Scientists discover novel African types of Salmonella linked to blood poisoning and death

The first global-scale genetic study of Salmonella Enteritidis bacteria, which is a major cause of blood poisoning and death in Africa and food poisoning in the Western World, has discovered that there are in fact three separate types.

22 Aug 2016

QUT molecular microbiologist developing new therapies to beat bacterial superbugs

QUT molecular microbiologist Makrina Totsika is at the forefront of research to develop new therapies to beat multi-drug resistant bacteria.

22 Aug 2016

Study estimates health care costs of gastrointestinal illnesses in Switzerland

In Switzerland, between 300,000 and 700,000 patients per year visit a doctor due to acute diarrhoea. Until now, the financial burden on the Swiss health care system had been completely unclear.

12 Aug 2016

NPS MedicineWise urges child care centres to increase awareness around misuse of antibiotics in young children

NPS MedicineWise has written to child care centres across Australia to enlist their support in responding to the growing problem of antibiotic resistance. Child care staff are well placed to help with education and increase awareness around the misuse of antibiotics in young children.

7 Jul 2016

Study sheds more light on how bacteria rapidly causes infectious diseases

Researchers at Umea University are first to discover that bacteria can multiply disease-inducing genes which are needed to rapidly cause infection.

1 Jul 2016

Spider venom helps investigate pain signals experienced by irritable bowel syndrome patients

Spiders have helped researchers from Australia and the US discover a new target for irritable bowel syndrome pain.

7 Jun 2016

Bacteriophage combinations show therapeutic potential in reducing C. difficile infections

A new University of Leicester study has confirmed the therapeutic potential of bacteriophage combinations to treat highly infectious bacteria C. difficile infections (CDI) while retaining a healthy gut.

6 Jun 2016

Global increase in sale of baby formula raises concerns about health of infants, mothers

A new study from The Australian National University has found a global boom in the sale of infant and baby formula, especially in China and Southeast Asia, raising concerns about the health of millions of mothers and their babies.

3 Jun 2016

University of Leicester researcher awarded grant to develop bacteriophages to target infant Shigella

A University of Leicester researcher has been awarded funding to develop bacteriophages to target bacterial infant diarrhoea in the developing world where it causes significant mortality.

28 May 2016

$ART trial: Adacolumn shows clinical benefit in refractory ulcerative colitis patients$

ART trial: Adacolumn shows clinical benefit in refractory ulcerative colitis patients

Data from the 48-week ART trial, presented today at the Digestive Disease Week meeting, showed that remission and response rates were 37.2% and 53.2% respectively at week 12, in patients with moderate-to-severe, steroid-dependent active ulcerative colitis (UC) with insufficient response or intolerance to immunosuppressants and / or biologics when treated with between five and eight sessions with Adacolumn.

26 May 2016

New data visualization platform identifies shortfalls in vaccine introduction and coverage

As the 69th World Health Assembly discusses progress on the Global Vaccine Action Plan, a new data visualization platform--from the International Vaccine Access Center at the Johns Hopkins Bloomberg School of Public Health--provides stark numbers on where shortfalls exist in vaccine introduction and coverage.

25 May 2016

New frozen faecal bank increases chances of curing a chronic health condition

A new frozen faecal bank that could save hundreds of lives and dramatically improve the quality of life of many more has been established at a Portsmouth hospital.

20 May 2016

Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

AbbVie, a global biopharmaceutical company, today announced The Lancet Oncology published results from the Phase 2, single arm, open label trial studying venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL) with 17p deletion.

17 May 2016

Janssen gets positive CHMP opinion for IMBRUVICA (ibrutinib) to treat patients with previously untreated CLL

Janssen-Cilag International NV today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a Positive Opinion, recommending broadening the existing marketing authorisation for ibrutinib as a single agent for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).

29 Apr 2016

AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

AstraZeneca today reported new Phase I extended follow-up data on osimertinib in both first- and second-line treatment of patients with non-small cell lung cancer (NSCLC), at the European Lung Cancer Conference (ELCC) 2016. Late-breaker presentations reinforced the efficacy and safety profile for osimertinib previously seen in the AURA clinical trials programme.

15 Apr 2016

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

RedHill Biopharma Ltd. (NASDAQ; RDHL) (TASE: RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it has initiated a randomized, double-blind, 2-arm parallel group Phase II clinical study in the U.S. evaluating the safety and efficacy of BEKINDA™ 12 mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

13 Apr 2016